首页|期刊导航|兰州大学学报(医学版)|外周T细胞淋巴瘤治疗进展

外周T细胞淋巴瘤治疗进展OA

Advances in the treatment of peripheral T-Cell lymphoma

中文摘要英文摘要

外周T细胞淋巴瘤(PTCL)是一组高度异质性、侵袭性强的成熟T细胞恶性肿瘤,在中国患病人数约占非霍奇金淋巴瘤的1/5,患者整体预后较差.本文基于世界卫生组织第5版造血与淋巴组织肿瘤分类,系统论述以维布妥昔单抗、组蛋白去乙酰化酶抑制剂、磷脂酰肌醇3-激酶抑制剂、Janus激酶抑制剂等为代表的新型靶向药物在初诊和复发/难治性外周T细胞淋巴瘤中的应用进展,并对个体化治疗策略进行展望,以期为临床诊疗与研究提供参考.

Peripheral T-cell lymphoma(PTCL)comprises a heterogeneous group of aggressive mature T-cell malignancies and accounts for approximately one-fifth of all non-Hodgkin lymphomas in China.Despite re-cent therapeutic advances,the overall prognosis of patients with PTCL remains poor.Based on the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours,this review provided a system-atic summary of recent advances in the management of newly diagnosed and relapsed/refractory PTCL,with a particular focus on novel targeted therapies,including brentuximab vedotin,histone deacetylase inhibitors,phosphoinositide 3-kinase inhibitors,and Janus kinase inhibitors.In addition,emerging individualized thera-peutic strategies and future perspectives were discussed,with the aim of providing updated evidence to guide clinical practice and future research.

赵文彦;张宇辰;蔡清清

中山大学肿瘤防治中心 内科,华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,广东 广州 510060中山大学肿瘤防治中心 内科,华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,广东 广州 510060中山大学肿瘤防治中心 内科,华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,广东 广州 510060

医药卫生

外周T细胞淋巴瘤一线治疗复发难治性治疗靶向治疗免疫治疗个体化治疗

peripheral T-cell lymphomafrontline therapyrelapsed/refractory treatmenttargeted therapyimmunotherapypersonalized treatment

《兰州大学学报(医学版)》 2026 (7)

1-13,13

四大慢病重大专项资助(2025ZD0544300)国家自然科学基金重点项目资助(82230001408)国家自然科学基金面上项目资助(82270199)广州市科技计划项目重点研发计划资助(2024B03J1291)

10.13885/j.issn.2097-681X.T20250065

评论